Gliomedin, Neurofascin, Caspr-1, and Contactin-1 have been identified as the target antigens in some GBS and CIDP patients (Pruss et al., 2011; Devaux et al., 2012; Ng et al., 2012; Querol et al., 2012; Figure 3). This evidence concerns the gene GLDN and chronic inflammatory demyelinating polyradiculoneuropathy.